作者: G. Leyhausen , H.C. Schröder , D.K. Schuster , A. Maidhof , H. Umezawa
DOI: 10.1016/0277-5379(85)90312-8
关键词:
摘要: Abstract Combinations of 1 -β- d -arabinofuranosylcytosine (araC), bleomycin (BLM) or adriamycin (ADM) with the dipeptide bestatin do not result in an enhanced vitro cytotoxicity macrophage-free L 5178 y mouse lymphoma cell system. However, macrophage-containing murine spleen lymphocytes causes a potentiating effect cytostatic drugs araC, BLM and ADM respect to their potencies inhibit DNA synthesis. In presence μg bestatin/ ml , ed 50 concentrations causing 50% reduction [ 3 H ]dThd incorporation were significantly lowered; 4.3 -fold studies araC BLM, 1.8 experiments ADM. Bestatin, given alone, displays stimulating on 5 into lymphocyte cultures within concentration range 0.1–10 μg/ml . contrast bestatin-stimulated lymphocytes, ConA-stimulated as well LPS-stimulated show higher sensitivity selected inhibiting These data should encourage practical use combination cancer treatment.